This page catalogs biotechnology and pharmaceutical companies developing therapeutics targeting the Notch signaling pathway and gamma-secretase for Parkinson's disease. The Notch pathway has emerged as a critical regulator of neurodegenerative processes through its roles in neural development, synaptic plasticity, and cellular stress responses["@lasky2020"]. In PD, Notch signaling intersects with key pathological processes including alpha-synuclein aggregation, dopaminergic neuron degeneration, neuroinflammation, and mitochondrial dysfunction["@song2019"].
While gamma-secretase inhibitors have shown preclinical promise for PD, selective Notch modulation remains a key challenge due to the pathway's pleiotropic functions throughout the body["@kelleher2015"].
The Notch family consists of four receptors (Notch1-4) and multiple ligands (Jagged1, Jagged2, DLL1, DLL3, DLL4). In PD, Notch signaling plays several important roles[@liu2018a]:
Gamma-secretase is a proteolytic enzyme complex that cleaves Notch receptors during canonical signaling. While gamma-secretase inhibitors (GSIs) have shown neuroprotective effects in PD models[@pan2020], they face significant challenges[@bittner2016]:
Status: Research Stage Program: MK-0752 and related Notch inhibitors
Merck has developed MK-0752, a potent gamma-secretase inhibitor that has been evaluated in clinical trials for oncology. Research has explored repurposing MK-0752 and related compounds for neurodegenerative diseases including PD and Alzheimer's disease.
Mechanism: Gamma-secretase inhibition reduces Notch signaling, which is dysregulated in PD patient neurons. Preclinical studies suggest reduced Notch activity may protect dopaminergic neurons from neurotoxin-induced damage.
Development Status: Preclinical/Research stage for PD; no active clinical trials in PD as of 2024.
Key References:
Status: Research Stage Program: Notch pathway modulators
Bristol-Myers Squibb has explored Notch signaling modulators in the context of cancer and inflammatory diseases. While not actively developing PD-specific programs, the company has contributed to understanding Notch biology that informs neurodegeneration research.
Relevant Research: BMS-906039 is a pan-Notch inhibitor that has been investigated in oncology. While not in active PD development, the compound has been used in research to understand Notch-dopaminergic neuron interactions.
Status: Phase 1 (AD, potential PD) Program: YH-4001 - Gamma-secretase modulator
Yuhan Corporation is developing YH-4001, a gamma-secretase modulator targeting APP processing in Alzheimer's disease. While currently in development for AD, the modulator approach may have relevance for PD in the future.
Mechanism: Modulation (rather than complete inhibition) of gamma-secretase activity shifts processing away from amyloid-beta peptide production while preserving essential Notch signaling and other vital functions. This selective modulation approach may provide a wider therapeutic window.
Clinical Status: Phase 1 clinical trials in Alzheimer's disease (2024).
See also: [Yuhan Corporation](/companies/yuhan-corporation) - for complete company profile
Status: Preclinical/Research Program: LRRK2 inhibitors with Notch considerations
While Denali's primary focus is on LRRK2 inhibition for PD, their research program considers pathway interactions between LRRK2 and Notch signaling. Studies have shown that LRRK2 kinase activity can affect Notch processing, providing potential combination opportunities.
Development Status: DNL151 (BIIB122) in Phase 2b for PD; early-stage programs explore pathway interactions.
See also: [Denali Therapeutics](/companies/denali) - for complete company profile
Status: Research Program: Protein clearance pathways
Prothena has developed expertise in protein clearance mechanisms relevant to neurodegenerative diseases. While their lead program (prasinezumab) targets alpha-synuclein, their research platform encompasses autophagy and protein quality control pathways that intersect with Notch signaling.
Relevant Research: Understanding of how Notch modulates autophagy-lysosomal pathways may inform future combination approaches.
Multiple academic centers have conducted preclinical research on Notch/gamma-secretase modulators for PD:
| Institution | Focus | Status |
|-------------|-------|--------|
| Johns Hopkins University | GSI-IX neuroprotection in MPTP model | Preclinical |
| Columbia University | Notch-alpha-syn interactions | Preclinical |
| University of Pennsylvania | iPSC models of Notch dysregulation | Research |
| Company | Drug/Mechanism | Indication | Stage | Notes |
|---------|----------------|------------|-------|-------|
| Merck | MK-0752 (GSI) | PD | Research | Repurposing potential |
| Yuhan | YH-4001 (GSM) | AD→PD potential | Phase 1 | Modulator approach |
| Denali | LRRK2 inhibitors | PD | Phase 2b | Pathway interactions |
| Prothena | Protein clearance | PD | Phase 2 | Autophagy modulators |
GSI = Gamma-Secretase Inhibitor GSM = Gamma-Secretase Modulator
The Notch pathway presents significant therapeutic challenges[@kelleher2015]:
Complete Notch inhibition may cause[@bittner2016]:
Optimal timing for Notch-targeted interventions:
Emerging strategies for Notch-targeted PD therapy:
Critical needs for clinical development:
Future directions include:
The following diagram shows the key molecular relationships involving Notch and Gamma-Secretase Modulators for Parkinson's Disease discovered through SciDEX knowledge graph analysis: